Moderna: 50 µg Booster Dose Of MRNA-1273.211 Meets Objectives For Bivalent Booster Candidates

Pre-market Movers: AXSM, SST, SAVA, ENSV, SMCI…

The following are some of the stocks making big moves in Tuesday’s pre-market trading (as of 07.50 A.M. ET).

In the Green

Axsome Therapeutics, Inc. (AXSM) is up over 34% at $43.89
Super Micro Computer, Inc. (SMCI) is up over 15% at $42.20
4D pharma plc (LBPS) is up over 13% at $5.27
BARK, Inc. (BARK) is up over 13% at $3.76
American Campus Communities, Inc. (ACC) is up over 12% at $65.00
Sharps Technology, Inc. (STSS) is up over 12% at $2.37
Zendesk, Inc. (ZEN) is up over 6% at $129.87
Banco Bradesco S.A. (BBD) is up over 5% at $4.41
ARC Document Solutions, Inc. (ARC) is up over 5% at $4.00
Fresh Vine Wine, Inc. (VINE) is up over 5% at $3.74

In the Red

System1, Inc. (SST) is down over 27% at $14.75
Cassava Sciences, Inc. (SAVA) is down over 18% at $20.55
Enservco Corporation (ENSV) is down over 16% at $3.04
NETGEAR, Inc. (NTGR) is down over 12% at $20.31
Indonesia Energy Corporation Limited (INDO) is down over 9% at $23.40
Origin Agritech Limited (SEED) is down over 8% at $7.36
ACADIA Pharmaceuticals Inc. (ACAD) is down over 7% at $20.70
Ecopetrol S.A. (EC) is down over 6% at $18.08
IsoPlexis Corporation (ISO) is down over 6% at $2.30

Russian Forces Launch Major Battle For Donbas

Russian forces have launched an all out attack on Ukrainian positions along the 480 kilometer front line in the eastern Donbas region.

Ukrainian President Volodymyr Zelensky announced in a video address on Monday that the battle for Donbas has already begun.

Deputy Prime Minister Iryna Vereshchuk said intense shelling is going on in Donbas.

Russian Defense Ministry claimed to have struck 1,260 targets overnight, but Ukrainian forces are making some successful counter-attacks south of Kharkiv, according to military analysts.

Moscow says it downed a Ukrainian MiG-29 jet in the Donetsk region.

Russia launched the latest round of offensive after its troops completed the regrouping, according to Ukraine’s defense ministry.

Civilians in Luhansk have been urged to evacuate after the town of Kreminna fell to Russian forces during heavy fighting.

The United Nations said nearly 5 million people have fled Ukraine after Russia invaded the country on February 24.

New Zealand has imposed new sanctions targeting 18 financial organizations that allegedly finance Russia’s invasion of Ukraine.
They make up about 80 percent of Russia’s total banking assets, Foreign Minister Nanaia Mahuta announced in a statement Tuesday.

Lockheed Martin Reaffirms FY22 Guidance

While reporting Q1 results on Tuesday, Lockheed Martin Corp. (LMT), on Tuesday, reaffirmed its financial guidance for fiscal 2022.

The company continues to project FY22 earnings of about $26.70 per share with net sales of about $66 billion. Also, the company expects FY22 business segment operating profit to be about $7.175 billion.

On average, 18 analysts polled by Thomson Reuters expect earnings of $26.80 per share on revenue of $66.11 billion for the year 2022. Analysts’ estimate typically exclude certain special items.

“Lockheed Martin had a solid start to the year by delivering margin expansion and free cash flow above our expectations despite recent Covid-surge impacts on our operations and supply chain. We remain confident in our guidance for the remainder of the year and our growth outlook beyond,” said Lockheed Martin Chairman, President and CEO James Taiclet.

Q1 Numbers

The company’s Q1 net income totaled $1.73 billion or $6.44 per share versus $1.84 billion or $6.56 per share last year. Revenue for the quarter fell 8.0% to $14.96 billion from $16.26 billion last year. Wall Street analysts estimated earnings of $6.21 per share and revenue of $15.55 billion for the quarter.

ProLogis Q1 Profit Increases, beats estimates

ProLogis (PLD) announced earnings for its first quarter that increased from last year and beat the Street estimates.

The company’s bottom line came in at $1.15 billion, or $1.54 per share. This compares with $0.37 billion, or $0.49 per share, in last year’s first quarter.

Excluding items, ProLogis reported adjusted earnings of $0.83 billion or $1.09 per share for the period.

Analysts on average had expected the company to earn $0.55 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

The company’s revenue for the quarter rose 6.1% to $1.22 billion from $1.15 billion last year.

ProLogis earnings at a glance (GAAP) :

-Earnings (Q1): $1.15 Bln. vs. $0.37 Bln. last year.
-EPS (Q1): $1.54 vs. $0.49 last year.
-Analyst Estimate: $0.55
-Revenue (Q1): $1.22 Bln vs. $1.15 Bln last year.

Full year EPS guidance: $5.10 to $5.16

To Tip, or Not to Tip? For Customers, That Is the Question.

Automated payment and the spread of tipping to every corner of the food-service business have helped workers weather the pandemic. But some consumers feel overwhelmed.

Send any friend a story

As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share.

By Christina Morales

Moderna: 50 µg Booster Dose Of MRNA-1273.211 Meets Objectives For Bivalent Booster Candidates

Moderna, Inc. (MRNA) reported new clinical data on its bivalent COVID-19 booster platform including data on its first bivalent booster candidate, mRNA-1273.211. The company said A50 µg booster dose of mRNA-1273.211 showed superiority against Beta, Delta and Omicron variants of concern one month after administration. The mRNA-1273.211 booster candidate was generally well tolerated in 300 study participants.

The company noted that the results indicate that the bivalent booster vaccine candidate mRNA-1273.211 at the 50 µg dose level induced higher antibody responses than the 50 µg mRNA-1273 booster, even when the variants were not included in the booster vaccine.

Stéphane Bancel, CEO of Moderna, said: “Our latest bivalent booster candidate, mRNA-1273.214, which combines the currently authorized Moderna COVID-19 booster with our Omicron-specific booster candidate, remains our lead candidate for the fall 2022 Northern Hemisphere booster?. We look forward to sharing initial data on mRNA-1273.214 later in the second quarter.”